ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants
The trial is being led by Dr.
“We are excited to move forward with dose escalation in this exciting trial using this anti-aging glyopeptide molecule
To obtain additional information and monitor updates regarding this trial please use the following link: Clinicaltrials.gov – Islet Transplantation Using PKX-001.
About
Cautionary Note Regarding Forward-Looking Statements
The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Refer to our risk factors set forth in our reports filed on Edgar.
This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in
View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005086/en/
President and Chief Executive Officer
Telephone: 740-434-5041
Email: csmith@protokinetix.com
Twitter: @ProtoKinetix
Source: